B- and T-cell immune responses elicited by the Comirnaty® COVID-19 vaccine in nursing-home residents.
Comirnaty®COVID-19 vaccine
Nursing-home residents
SARS-CoV-2
SARS-CoV-2 S T cells
SARS-CoV-2 S antibodies
Journal
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
19
04
2021
revised:
01
06
2021
accepted:
10
06
2021
pubmed:
27
6
2021
medline:
15
12
2021
entrez:
26
6
2021
Statut:
ppublish
Résumé
The immunogenicity of the Comirnaty® vaccine against coronavirus disease 2019 (COVID-19) has not been adequately studied in elderly people with comorbidities. We assessed antibody and T-cell responses targeted to the S protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following full vaccination in nursing-home residents. Sixty nursing-home residents (44 female, age 53-100 years), of whom ten had previously been diagnosed with COVID-19, and 18 healthy controls (15 female, age 27-54 years) were recruited. Pre- and post-vaccination blood specimens were available for quantification of total antibodies binding the SARS-CoV-2 S protein and for enumeration of SARS-CoV-2 S-reactive IFN-γ CD4 The seroconversion rate in (presumably) SARS-CoV-2-naïve nursing-home residents (41/43, 95.3%) was similar to that in controls (17/18, 94.4%). A booster effect was documented in post-vaccination samples of nursing-home residents with prior COVID-19. Plasma antibody levels were higher (p < 0.01) in recovered nursing-home residents (all 2500 IU/mL) than in individuals across the other two groups (median 1120 IU/mL in naïve nursing-home residents and 2211 IU/ml in controls). A large percentage of nursing-home residents had SARS-CoV-2 S-reactive IFN-γ CD8 The Comirnaty COVID-19 vaccine elicits robust SARS-CoV-2 S antibody responses in nursing-home residents. Nevertheless, the rate and frequency of detectable SARS-CoV-2 IFN-γ T-cell responses after vaccination was lower in nursing-home residents than in controls.
Identifiants
pubmed: 34174397
pii: S1198-743X(21)00332-3
doi: 10.1016/j.cmi.2021.06.013
pmc: PMC8223011
pii:
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
IFNG protein, human
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1672-1677Informations de copyright
Copyright © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Références
J Clin Virol. 2021 Apr;137:104784
pubmed: 33711693
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
PLoS One. 2021 Jan 25;16(1):e0245532
pubmed: 33493185
J Infect Dis. 2021 Jul 2;224(1):70-80
pubmed: 33822097
Nat Commun. 2021 Apr 6;12(1):2055
pubmed: 33824342
Lancet. 2021 May 1;397(10285):1646-1657
pubmed: 33901420
J Med Virol. 2021 Jan;93(1):375-382
pubmed: 32579268
Front Immunol. 2020 Oct 14;11:583019
pubmed: 33178213
J Clin Microbiol. 2021 Mar 19;59(4):
pubmed: 33483360
Nature. 2021 Apr;592(7853):283-289
pubmed: 33524990
Sci Transl Med. 2021 Dec 7;:eabi8961
pubmed: 34874183
Age Ageing. 2021 Feb 26;50(2):279-283
pubmed: 33320183
J Clin Invest. 2021 May 17;131(10):
pubmed: 33830946
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Transplantation. 2021 Jun 1;105(6):1372-1380
pubmed: 33729741
Cell Rep. 2021 Aug 24;36(8):109570
pubmed: 34390647
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279